A
15.36
-1.18 (-7.13%)
| Penutupan Terdahulu | 16.54 |
| Buka | 16.29 |
| Jumlah Dagangan | 73,467 |
| Purata Dagangan (3B) | 105,003 |
| Modal Pasaran | 319,375,616 |
| Harga / Jualan (P/S) | 1.49 |
| Harga / Buku (P/B) | 0.740 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Margin Keuntungan | -41.07% |
| Margin Operasi (TTM) | -39.88% |
| EPS Cair (TTM) | -4.40 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -25.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.18% |
| Nisbah Semasa (MRQ) | 3.53 |
| Aliran Tunai Operasi (OCF TTM) | -30.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 9.06 M |
| Pulangan Atas Aset (ROA TTM) | -5.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - General (US) | Menaik | Menurun |
| Drug Manufacturers - General (Global) | Menaik | Menurun | |
| Stok | Amarin Corporation plc | Bercampur | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - General |
| % Dimiliki oleh Orang Dalam | 1.88% |
| % Dimiliki oleh Institusi | 17.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sarissa Capital Management Lp | 30 Sep 2025 | 1,242,527 |
| Eversept Partners, Lp | 30 Sep 2025 | 167,276 |
| Scp Investment, Lp | 30 Sep 2025 | 100,000 |
| Longitude (Cayman) Ltd. | 31 Dec 2024 | 81,000 |
| Waterfront Wealth Inc. | 30 Sep 2025 | 77,960 |
| Quinn Opportunity Partners Llc | 30 Sep 2025 | 58,461 |
| Lcm Capital Management Inc | 30 Sep 2025 | 42,762 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |